公开(公告)号：WO2016020324A1

公开(公告)日：2016-02-11

申请号：PCT/EP2015/067822

申请日：2015-08-03

Applicant: BASF SE

Inventor： VIERTELHAUS, Martin ,  CHIODO, Tiziana ,  SALVADOR, Beate ,  VOSSEN, Marcus ,  HAFNER, Andreas ,  HINTERMANN, Tobias ,  WEISHAAR, Walter ,  HELLMANN, Rolf

IPC: C07D213/40

CPC classification number: A61K31/4402 ,  C07D213/40

Abstract: The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and sol-vents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.

Abstract translation: 本发明主要涉及包含式1化合物和选自共晶体形成剂和溶剂的第二种化合物的多组分晶体。 本发明还涉及包含这种多组分晶体的药物组合物。 此外，本发明涉及制备所述多组分晶体的方法。 本发明还涉及使用所述多组分晶体或药物组合物治疗疾病的若干方面。

公开(公告)号：WO2014023682A1

公开(公告)日：2014-02-13

申请号：PCT/EP2013/066360

申请日：2013-08-05

Applicant: BASF SE ,  BASF SCHWEIZ AG

Inventor： HAFNER, Andreas ,  BLATTER, Fritz ,  RÖDEL, Eva ,  SZELAGIEWICZ, Martin ,  CHIODO, Tiziana ,  HINTERMANN, Tobias ,  SALVADOR, Beate ,  VOSSEN, Marcus

IPC: C07D249/08 ,  A61K31/4196 ,  A61P7/00

CPC classification number: C07D213/81 ,  C07B2200/13 ,  C07D249/08

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN:Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.

Abstract translation: 本发明涉及包含式（1）化合物（4- [3,5-双（2-羟基苯基）-1H-1,2,4-三唑-1-基）的多组分结晶体（共晶体） ]苯甲酸; INN：Deferasirox）式（1）和式（2）化合物（异烟酰胺;吡啶-4-甲酰胺）式（2），以及其获得方法。

公开(公告)号：WO2013186726A2

公开(公告)日：2013-12-19

申请号：PCT/IB2013/054832

申请日：2013-06-13

Applicant: BASF SE ,  BASF SCHWEIZ AG ,  BASF (CHINA) COMPANY LIMITED

Inventor： CHIODO, Tiziana ,  HAFNER, Andreas ,  HINTERMANN, Tobias ,  SALVADOR, Beate ,  SZELAGIEWICZ, Martin ,  BLATTER, Fritz ,  SIEBENHAAR, Bernd ,  VOSSEN, Marcus

CPC classification number: C07D417/12 ,  A61K31/506 ,  C07B2200/07 ,  C07B2200/13 ,  C07C35/12 ,  C07C47/58 ,  C07C65/03 ,  C07C69/84 ,  C07D213/82 ,  C07D309/40 ,  A61K2300/00

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula 1 (INN: Dasatinib) and a second compound selected from methyl-4-hydroxybenzoate, or nicotinamide, or ethyl gallate, or methyl gallate, or propyl gallate, or ethyl maltol or vanillin, or men- thol, or (1R,2S,5R)-(-)-menthol,as well as to a process for obtaining the same.

Abstract translation: 本发明涉及包含式1化合物（INN：达沙替尼）和选自甲基-4-羟基苯甲酸酯或烟酰胺或没食子酸乙酯的第二化合物或没食子酸甲酯或丙基的多组分结晶体（共晶体） 乙酸麦芽糖醇或香草醛，或者吗啉，或（1R，2S，5R） - （ - ） - 薄荷醇，以及获得它们的方法。

公开(公告)号：WO2012136606A1

公开(公告)日：2012-10-11

申请号：PCT/EP2012/055920

申请日：2012-04-02

Applicant: BASF SE ,  HINTERMANN, Tobias ,  CARROY, Antoine ,  LORDELOT, Caroline ,  BAUER, Didier ,  KOHLI STECK, Rachel ,  FALLER, Marc

Inventor： HINTERMANN, Tobias ,  CARROY, Antoine ,  LORDELOT, Caroline ,  BAUER, Didier ,  KOHLI STECK, Rachel ,  FALLER, Marc

IPC: B01J31/02 ,  B01J31/22 ,  C08G18/22

CPC classification number: C09D175/16 ,  B01J31/0208 ,  B01J31/2234 ,  B01J2231/14 ,  B01J2231/48 ,  B01J2531/46 ,  C08G18/222 ,  C08G18/6229 ,  C08G18/68 ,  C08G18/792 ,  C09J175/04 ,  Y02P20/52

Abstract: A titanium-oxo-chelate catalyst formulation, comprising: (i) at least one compound of the formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 independently of each other are for example hydrogen, halogen, C 1 -C 20 alkyl, C 6 -C 14 aryl which is unsubstituted or substituted; or R 1 , R 2 and R 3 and/or R 4 , R 5 and R 6 and/or R 7 , R 8 and R 9 and/or R 10 , R 11 and R 12 together with the C-atom to which they are attached each form a C 6 - C 14 aryl group which is unsubstituted or substituted; or R 1 and R 2 and/or R 4 and R 5 and/or R 7 and R 8 and/or R 10 and R 11 together with the C-atom to which they are attached form a 5- to 7-membered carbocyclic ring; at least one chelate ligand compound of the formula (lla), (lIb) or (lIc), wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined as above for formula (I), is suitable as photolatent catalyst formulation for polymerizing compounds, which are capable to crosslink in the presence of a Lewis acid.

Abstract translation: 一种钛 - 氧代 - 螯合催化剂制剂，其包含：（i）至少一种式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8，R 9，R 10，R 11和R 12独立地 彼此是例如氢，卤素，未取代或取代的C 1 -C 20烷基，C 6 -C 14芳基; 或R 1，R 2和R 3和/或R 4，R 5和R 6和/或R 7，R 8和R 9和/或R 10，R 11和R 12与它们所连接的C原子一起形成C 6 -C 14芳基， 未取代或取代的; 或R 1和R 2和/或R 4和R 5和/或R 7和R 8和/或R 10和R 11与它们所连接的C原子一起形成5-至7-元碳环; 至少一种式（Ⅰla），（IIIb）或（IIIc）的螯合配体化合物，其中R 1，R 2，R 3，R 4，R 5和R 6如上文对式（I）所定义，适合作为用于 聚合化合物，其能够在路易斯酸存在下交联。

公开(公告)号：WO2015032646A1

公开(公告)日：2015-03-12

申请号：PCT/EP2014/068007

申请日：2014-08-25

Applicant: BASF SE

Inventor： HINTERMANN, Tobias ,  SCHWAB, Matthias Georg ,  CHA, Kitty Chih-Pei ,  WEITZ, Thomas ,  SCHÄFER, Ansgar ,  MÜLLER, Imke Britta

IPC: C01B31/04 ,  H01L29/66 ,  H01L29/778 ,  H01L29/06 ,  H01L29/16

CPC classification number: C01B31/0492 ,  C01B32/196 ,  C01B2204/06 ,  H01L29/0669 ,  H01L29/0673 ,  H01L29/1606 ,  H01L29/66037 ,  H01L29/66045 ,  H01L29/7781 ,  H01L29/78

Abstract: The present invention relates to a process for purifying graphene nanoribbons, which comprises: - bringing into contact a composition comprising graphene nanoribbons GNR1 and one or more contaminants with a liquid medium comprising a dispersant, and dispersing the graphene nanoribbons GNR1 in the liquid medium so as to obtain a liquid dispersion of the graphene nanoribbons GNR1, - subjecting the liquid dispersion of the graphene nanoribbons GNR1 to a separation treatment so as to at least partly remove the one or more contaminants, thereby obtaining a liquid dispersion of purified graphene nanoribbons GNR1.

Abstract translation: 本发明涉及一种用于纯化石墨烯纳米带的方法，其包括：使包含石墨烯纳米带GNR1和一种或多种污染物的组合物与包含分散剂的液体介质接触，并将石墨烯纳米带GNR1分散在液体介质中，以便 以获得石墨烯纳米带GNR1的液体分散体， - 使石墨烯纳米带GNR1的液体分散体进行分离处理，以至少部分除去一种或多种污染物，从而获得纯化的石墨烯纳米带GNR1的液体分散体。

公开(公告)号：WO2015011120A2

公开(公告)日：2015-01-29

申请号：PCT/EP2014/065675

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER, Andreas ,  BLATTER, Fritz ,  SZELAGIEWICZ, Martin ,  SIEBENHAAR, Bernd ,  CHIODO, Tiziana ,  HINTERMANN, Tobias ,  SALVADOR, Beate ,  VOSSEN, Marcus

IPC: A61K31/506

CPC classification number: C07D417/12 ,  C07B2200/13 ,  C07D275/06

Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

Abstract translation: 本发明主要涉及分子结晶物质，优选结晶形式的达沙替尼的盐，其包含式1化合物，优选式1化合物的阳离子和选自 由戊二酸，烟酸和糖精组成的组，优选其阴离子。 本发明还涉及包含这种物质的药物组合物。 此外，本发明涉及制备所述物质的方法。 本发明还涉及使用所述物质或药物组合物治疗疾病的几个方面。

公开(公告)号：WO2013084130A1

公开(公告)日：2013-06-13

申请号：PCT/IB2012/056907

申请日：2012-12-03

Applicant: BASF SE ,  HAFNER, Andreas ,  HINTERMANN, Tobias ,  BLATTER, Fritz ,  RÖDEL, Eva ,  BASF (CHINA) COMPANY LIMITED

Inventor： HAFNER, Andreas ,  HINTERMANN, Tobias ,  BLATTER, Fritz ,  RÖDEL, Eva

IPC: C07D403/10 ,  A61K31/506 ,  A61P31/10

CPC classification number: A61K31/506 ,  A61K31/194 ,  C07D403/10 ,  A61K2300/00

Abstract: A novel solid form of Voriconazole comprises the active ingredient (2R,3S)-2-(2,4- difluorophenyl)- 3-(5-fluoropyrimidin- 4-yl)-1 -(1H-1,2,4-triazol-1 -yl)butan-2-ol and fumaric acid. The solid composition comprising the two components shows improved properties such as water solubility, crystallization behavior and stability.

Abstract translation: 一种新型固体形式的伏立康唑包括活性成分（2R，3S）-2-（2,4-二氟苯基）-3-（5-氟嘧啶-4-基）-1-（1H-1,2,4-三唑 -1-基）丁-2-醇和富马酸。 包含两种组分的固体组合物显示出改进的性能，例如水溶性，结晶行为和稳定性。

公开(公告)号：WO2013014604A1

公开(公告)日：2013-01-31

申请号：PCT/IB2012/053751

申请日：2012-07-24

Applicant: BASF SE ,  HAFNER, Andreas ,  HINTERMANN, Tobias ,  SZELAGIEWICZ, Martin ,  SIEBENHAAR, Bernd ,  BLATTER, Fritz ,  BASF (CHINA) COMPANY LIMITED

Inventor： HAFNER, Andreas ,  HINTERMANN, Tobias ,  SZELAGIEWICZ, Martin ,  SIEBENHAAR, Bernd ,  BLATTER, Fritz

IPC: C07D205/08 ,  C07D207/16

CPC classification number: C07D205/08 ,  C07B57/00

Abstract: Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purification of Ezetimibe is also disclosed.

Abstract translation: 提供了包含式1化合物（依泽替米贝）和脯氨酸或脯氨酸衍生物或其水合物/溶剂化物的混合物的结晶组合物，以及其获得方法。 还公开了纯化依泽替米贝的方法。

公开(公告)号：WO2011032837A1

公开(公告)日：2011-03-24

申请号：PCT/EP2010/062779

申请日：2010-09-01

Applicant: BASF SE ,  HINTERMANN, Tobias ,  BAUER, Didier ,  CARROY, Antoine ,  LORDELOT, Caroline ,  KOHLI STECK, Rachel

Inventor： HINTERMANN, Tobias ,  BAUER, Didier ,  CARROY, Antoine ,  LORDELOT, Caroline ,  KOHLI STECK, Rachel

IPC: B01J31/02 ,  B01J31/22 ,  C08G18/22

CPC classification number: B01J31/2234 ,  B01J31/0214 ,  B01J31/223 ,  B01J2231/34 ,  B01J2531/46 ,  B33Y70/00 ,  C08G18/222 ,  C08G18/6229 ,  C08G18/792 ,  C09D175/04

Abstract: The present invention provides photolatent Ti-chelate catalyst compounds of formula (I), wherein R 1 is for example C 6 -C 14 aryl which is substituted by one or more R' 2 , R' 3 or R' 4 ; or the two R 1 together are unsubstituted linear or branched C 1 -C 12 alkylene; R 2 , R 3 , R 4 , R' 2 , R' 3 , and R' 4 independently of each other are for example hydrogen, halogen or linear or branched C 1 -C 20 alkyl; R 5 , R 6 and R 7 independently of each other are hydrogen, linear or branched C 1 - C 20 alkyl, C 6 -C 14 aryl, Br or Cl, provided that not more than one of R 5 , R 6 and R 7 is hydrogen; as well as formulations comprising said compounds and defined 1,3-diketones.

Abstract translation: 本发明提供式（I）的光催化钛螯合催化剂化合物，其中R 1为例如被一个或多个R'2，R'3或R'4取代的C6-C14芳基; 或两个R 1一起是未取代的直链或支链C 1 -C 12亚烷基; R 2，R 3，R 4，R'2，R'3和R 4彼此独立地是例如氢，卤素或直链或支链C 1 -C 20烷基; R 5，R 6和R 7彼此独立地是氢，直链或支链C 1 -C 20烷基，C 6 -C 14芳基，Br或Cl，条件是不多于一个R 5，R 6和R 7是氢; 以及包含所述化合物和所定义的1,3-二酮的制剂。

公开(公告)号：WO2018083613A1

公开(公告)日：2018-05-11

申请号：PCT/IB2017/056806

申请日：2017-11-02

Applicant: BASF SE ,  BASF (CHINA) COMPANY LIMITED

Inventor： HINTERMANN, Tobias ,  BUJARD, Patrice ,  KOSTRO, Andre ,  VON MUEHLENEN, Adrian ,  GARRIDO SEGURA, Cristobal

IPC: G02B6/26 ,  F21V8/00 ,  F21S11/00

Abstract: A daylight illumination system for integration into a building or larger vehicle comprises a translucent facade element (800) containing a glass sheet and a light redirection element (302 or 708), and a light transport channel (801) for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building, characterised in that the light redirection element (302 or 708) is formed as a structured polymer film or sheet attached to a glass sheet of the facade element (800) and is configured for changing the direction of incident light into the about horizontal light transport channel.

Abstract translation: 用于集成到建筑物或较大车辆中的日光照明系统包括：包含玻璃板和光重定向元件（302或708）的半透明立面元件（800）;以及光传输通道（801） ），用于将光水平地引导到建筑物的内部，光传输通道包括附接到所述外立面元件的内侧的一个开口以及朝向建筑物的内部的至少一个开口，其特征在于，光重定向元件（302 或708）形成为附接到外立面元件（800）的玻璃片上的结构化聚合物膜或片并且被配置用于改变进入大约水平光传输通道的入射光的方向。